This research work deals with the design and development of the solid lipid nanoparticles of Losartan to improve solubility of poorly soluble drug. Losartan solid lipid nanoparticles are formed using hot homogenization technique followed by ultrasonication technique. Experiment trend is predicted using the standard calibration curve. The parameters studied are the percent drug release, entrapment efficiency, particle size of SLN and the in-vitro drug release of prepared SLN. The results obtained in this research work clearly indicated that the developed solid lipid nanoparticle delivery system for the highly lipophilic drug, Losartan using stearic acid, glyceryl monostearate as carrier matrices can be used effectively for hypertension
Solid lipid nanoparticles (SLN) are the heart of nanotechnology's tremendous development, with multi...
The era of nanotechnology has revolutionized the drug delivery system and persuades new research str...
Solid lipid nanoparticles (SLN) containing or not (S)-(+)-2-(4-isobutylphenyl)propionic acid (ibupro...
Objective: The aim of the current research is to formulate and evaluate Trandolapril loaded solid li...
Solid lipid nanoparticles (SLN) are a type of nanoparticles. They are submicron colloidal carriers w...
ABSTRACT The solid lipid nanoparticles possess a lipid core matrix in a nanometer range, stabilized...
Candesertan cilexetil is a Biopharmaccutics Classification System (BCS) Class II drug possessing hig...
The present study describes preparation and evaluation of nanoparticulate systems containing losarta...
Solid lipid nanoparticles (SLNs) of zolmitriptan were produced by solvent emulsification-diffusion t...
ABSTRACT Irbesartan is an antihypertensive with limited bioavailability and solid lipid nanoparticle...
Solid lipid nanoparticles (SLNs) were recently developed in 1991 having particle size range from 10 ...
Solid Lipid Nanoparticles are at the forefront of the rapidly developing field of nanotechnology wit...
Valsartan is a potent and specific competitive angiotensin II antagonist which is used in the manage...
From last thirty years, solid lipid nanoparticles (SLNs) gain much importance as drug delivery vehic...
SLNs are basically composed of a solid lipid core in nanometer ranges stabilized by a layer of emuls...
Solid lipid nanoparticles (SLN) are the heart of nanotechnology's tremendous development, with multi...
The era of nanotechnology has revolutionized the drug delivery system and persuades new research str...
Solid lipid nanoparticles (SLN) containing or not (S)-(+)-2-(4-isobutylphenyl)propionic acid (ibupro...
Objective: The aim of the current research is to formulate and evaluate Trandolapril loaded solid li...
Solid lipid nanoparticles (SLN) are a type of nanoparticles. They are submicron colloidal carriers w...
ABSTRACT The solid lipid nanoparticles possess a lipid core matrix in a nanometer range, stabilized...
Candesertan cilexetil is a Biopharmaccutics Classification System (BCS) Class II drug possessing hig...
The present study describes preparation and evaluation of nanoparticulate systems containing losarta...
Solid lipid nanoparticles (SLNs) of zolmitriptan were produced by solvent emulsification-diffusion t...
ABSTRACT Irbesartan is an antihypertensive with limited bioavailability and solid lipid nanoparticle...
Solid lipid nanoparticles (SLNs) were recently developed in 1991 having particle size range from 10 ...
Solid Lipid Nanoparticles are at the forefront of the rapidly developing field of nanotechnology wit...
Valsartan is a potent and specific competitive angiotensin II antagonist which is used in the manage...
From last thirty years, solid lipid nanoparticles (SLNs) gain much importance as drug delivery vehic...
SLNs are basically composed of a solid lipid core in nanometer ranges stabilized by a layer of emuls...
Solid lipid nanoparticles (SLN) are the heart of nanotechnology's tremendous development, with multi...
The era of nanotechnology has revolutionized the drug delivery system and persuades new research str...
Solid lipid nanoparticles (SLN) containing or not (S)-(+)-2-(4-isobutylphenyl)propionic acid (ibupro...